Works by Othus, Megan

Results: 80
    1
    2
    3
    4

    Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review.

    Published in:
    Cancers, 2023, v. 15, n. 9, p. 2561, doi. 10.3390/cancers15092561
    By:
    • Eljilany, Islam;
    • Noor, Arish;
    • Paravathaneni, Mahati;
    • Yassine, Ibrahim;
    • Lee, Sandra J.;
    • Othus, Megan;
    • Moon, James;
    • Kirkwood, John M.;
    • Sondak, Vernon K.;
    • Ribas, Antoni;
    • Grossmann, Kenneth F.;
    • Tarhini, Ahmad A.
    Publication type:
    Article
    5
    6

    Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms.

    Published in:
    Cancers, 2022, v. 14, n. 12, p. 2934, doi. 10.3390/cancers14122934
    By:
    • Godwin, Colin D.;
    • Rodríguez-Arbolí, Eduardo;
    • Othus, Megan;
    • Halpern, Anna B.;
    • Appelbaum, Jacob S.;
    • Percival, Mary-Elizabeth M.;
    • Hendrie, Paul C.;
    • Oehler, Vivian G.;
    • Keel, Siobán B.;
    • Abkowitz, Janis L.;
    • Cooper, Jason P.;
    • Cassaday, Ryan D.;
    • Estey, Elihu H.;
    • Walter, Roland B.
    Publication type:
    Article
    7

    Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

    Published in:
    Cancers, 2020, v. 12, n. 9, p. 2339, doi. 10.3390/cancers12092339
    By:
    • Morsink, Linde M.;
    • Sandmaier, Brenda M.;
    • Othus, Megan;
    • Palmieri, Raffaele;
    • Granot, Noa;
    • Bezerra, Evandro D.;
    • Wood, Brent L.;
    • Mielcarek, Marco;
    • Schoch, Gary;
    • Davis, Chris;
    • Flowers, Mary E. D.;
    • Deeg, H. Joachim;
    • Appelbaum, Frederick R.;
    • Storb, Rainer;
    • Walter, Roland B.
    Publication type:
    Article
    8

    Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.

    Published in:
    Diabetes Care, 2022, v. 45, n. 5, p. 1170, doi. 10.2337/dc21-2213
    By:
    • Chen, Xuan;
    • Affinati, Alison H.;
    • Lee, Yungchun;
    • Turcu, Adina F.;
    • Henry, Norah Lynn;
    • Schiopu, Elena;
    • Qin, Angel;
    • Othus, Megan;
    • Clauw, Dan;
    • Ramnath, Nithya;
    • Zhao, Lili
    Publication type:
    Article
    9
    10

    A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 2, p. 473, doi. 10.1080/10428194.2022.2148212
    By:
    • Assouline, Sarit;
    • Michaelis, Laura C.;
    • Othus, Megan;
    • Hay, Annette E.;
    • Walter, Roland B.;
    • Jacoby, Meagan A.;
    • Schroeder, Mark A.;
    • Uy, Geoffrey L.;
    • Law, Lisa Y.;
    • Cheema, Faisal;
    • Sweet, Kendra L.;
    • Asch, Adam S.;
    • Liu, Jijun;
    • Moseley, Anna B.;
    • Maher, Tracy;
    • Kingsbury, Laura L.;
    • Fang, Min;
    • Radich, Jerald;
    • Little, Richard F.;
    • Erba, Harry P.
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18

    Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm

    Published in:
    2020
    By:
    • Palmieri, Raffaele;
    • Buckley, Sarah A.;
    • Othus, Megan;
    • Halpern, Anna B.;
    • Percival, Mary-Elizabeth M.;
    • Scott, Bart L.;
    • Hendrie, Paul C.;
    • Becker, Pamela S.;
    • Oehler, Vivian G.;
    • Estey, Elihu H.;
    • Walter, Roland B.
    Publication type:
    Letter
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30

    Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

    Published in:
    American Journal of Hematology, 2018, v. 93, n. 2, p. E49, doi. 10.1002/ajh.24980
    By:
    • Walter, Roland B.;
    • Michaelis, Laura C.;
    • Othus, Megan;
    • Uy, Geoffrey L.;
    • Radich, Jerald P.;
    • Little, Richard F.;
    • Hita, Sandi;
    • Saini, Lalit;
    • Foran, James M.;
    • Gerds, Aaron T.;
    • Klepin, Heidi D.;
    • Hay, Annette E.;
    • Assouline, Sarit;
    • Lancet, Jeffrey E.;
    • Couban, Stephen;
    • Litzow, Mark R.;
    • Stone, Richard M.;
    • Erba, Harry P.
    Publication type:
    Article
    31

    G-CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.

    Published in:
    American Journal of Hematology, 2015, v. 90, n. 4, p. 295, doi. 10.1002/ajh.23927
    By:
    • Becker, Pamela S.;
    • Medeiros, Bruno C.;
    • Stein, Anthony S.;
    • Othus, Megan;
    • Appelbaum, Frederick R.;
    • Forman, Stephen J.;
    • Scott, Bart L.;
    • Hendrie, Paul C.;
    • Gardner, Kelda M.;
    • Pagel, John M.;
    • Walter, Roland B.;
    • Parks, Cynthia;
    • Wood, Brent L.;
    • Abkowitz, Janis L.;
    • Estey, Elihu H.
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38

    Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients.

    Published in:
    Biomarker Research, 2023, v. 11, n. 1, p. 1, doi. 10.1186/s40364-023-00461-0
    By:
    • Pogosova-Agadjanyan, Era L.;
    • Hua, Xing;
    • Othus, Megan;
    • Appelbaum, Frederick R.;
    • Chauncey, Thomas R.;
    • Erba, Harry P.;
    • Fitzgibbon, Matthew P.;
    • Jenkins, Isaac C.;
    • Fang, Min;
    • Lee, Stanley C.;
    • Moseley, Anna;
    • Naru, Jasmine;
    • Radich, Jerald P.;
    • Smith, Jenny L.;
    • Willborg, Brooke E.;
    • Willman, Cheryl L.;
    • Wu, Feinan;
    • Meshinchi, Soheil;
    • Stirewalt, Derek L.
    Publication type:
    Article
    39

    AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report.

    Published in:
    Biomarker Research, 2020, v. 8, n. 1, p. 1, doi. 10.1186/s40364-020-00208-1
    By:
    • Pogosova-Agadjanyan, Era L.;
    • Moseley, Anna;
    • Othus, Megan;
    • Appelbaum, Frederick R.;
    • Chauncey, Thomas R.;
    • Chen, I-Ming L.;
    • Erba, Harry P.;
    • Godwin, John E.;
    • Jenkins, Isaac C.;
    • Fang, Min;
    • Huynh, Mike;
    • Kopecky, Kenneth J.;
    • List, Alan F.;
    • Naru, Jasmine;
    • Radich, Jerald P.;
    • Stevens, Emily;
    • Willborg, Brooke E.;
    • Willman, Cheryl L.;
    • Wood, Brent L.;
    • Zhang, Qing
    Publication type:
    Article
    40
    41
    42

    A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort.

    Published in:
    Cancer (0008543X), 2021, v. 127, n. 17, p. 3194, doi. 10.1002/cncr.33591
    By:
    • Patel, Sandip Pravin;
    • Mayerson, Edward;
    • Chae, Young Kwang;
    • Strosberg, Jonathan;
    • Wang, Jue;
    • Konda, Bhavana;
    • Hayward, Jourdain;
    • McLeod, Christine M.;
    • Chen, Helen X.;
    • Sharon, Elad;
    • Othus, Megan;
    • Ryan, Christopher W.;
    • Plets, Melissa;
    • Blanke, Charles D.;
    • Kurzrock, Razelle
    Publication type:
    Article
    43
    44
    45
    46
    47
    48
    49
    50